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Abstract
Mycobacteria develop strategies to evade the host immune system. Among them, mycobacterial LAM or PIMs inhibit the
expression of pro-inflammatory cytokines by activated macrophages. Here, using synthetic PIM analogues, we analyzed the
mode of action of PIM anti-inflammatory effects. Synthetic PIM1 isomer and PIM2 mimetic potently inhibit TNF and IL-12 p40
expression induced by TLR2 or TLR4 pathways, but not by TLR9, in murine macrophages. We show inhibition of LPS binding
to TLR4/MD2/CD14 expressing HEK cells by PIM1 and PIM2 analogues. More specifically, the binding of LPS to CD14 was
inhibited by PIM1 and PIM2 analogues. CD14 was dispensable for PIM1 and PIM2 analogues functional inhibition of TLR2
agonists induced TNF, as shown in CD14-deficient macrophages. The use of rough-LPS, that stimulates TLR4 pathway
independently of CD14, allowed to discriminate between CD14-dependent and CD14-independent anti-inflammatory
effects of PIMs on LPS-induced macrophage responses. PIM1 and PIM2 analogues inhibited LPS-induced TNF release by a
CD14-dependent pathway, while IL-12 p40 inhibition was CD14-independent, suggesting that PIMs have multifold
inhibitory effects on the TLR4 signalling pathway.
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Introduction
Mycobacterium tuberculosis induces the formation of granulo-
ma, a ‘‘super cellular’’ structure involving cells both from the
innate and the adaptive immune responses, that may play a dual
role, for infection containment on the one side, and immune
evasion and persistence of viable mycobacteria on the other side.
M. tuberculosis are recognized by multiple pattern recognition
receptors expressed on alveolar macrophages, their primary host
cells, which in turn modulate the immune responses by secreting
cytokines and chemokines. TNF, an essential mediator for
granuloma formation, is essential for controlling M. tuberculosis
infection [1,2], together with IL-12, IFNc or IL-1 [3–9].
Macrophages also express cytokines that dampen the immune
response such as IL-10. Mycobacteria produce a series of
molecules modulating the immune system, including the protein
ESAT-6, lipomannans (LM), mannose-capped lipoarabinoman-
nan (ManLAM) and their precursors mono- to tetra-acylated
phosphatidyl-myo-inositol mannosides (PIM; lyso-PIM for one acyl,
PIM for two acyl, Ac1PIM for three acyl and Ac2PIM for four
acyl, respectively) [10–19].
Several pattern recognition receptors have been implicated in
the recognition of mycobacterial LAM, LM and PIMs by
macrophages and dendritic cells, such as Toll-like receptors
(TLRs) and C-type lectin mannose receptor (CD206) and
dendritic cell-specific intercellular adhesion molecule-3 grabbing
nonintegrin (DC-SIGN/CD209) [15–17,20–28]. Tri and tetra-
acylated LM fractions are pro-inflammatory through TLR2,
TLR4 and myeloid differentiation protein 88 (MyD88), and
purified fractions of dimannoside PIM2 and hexamannoside
PIM6, the two most abundant classes of PIMs found in M.
tuberculosis H37Rv and M. bovis BCG (bacillus Calmette Gue ´rin),
may be proinflammatory through TLR2 [29,30]. Higher-order
PIMs with mannose cap-like structures seem to associate with
human mannose receptor and to contribute to phagosome-
lysosome fusion depending of their degree of acylation, while
PIM2 are recognized by DC-SIGN independently of their
acylation degree [31].
Among the anti-inflammatory activities, ManLAM inhibition of
LPS-induced IL-12 production in dendritic cells was attributed to
DC-SIGN [15]. We showed recently that di-acylated LM, but also
purified fractions of PIM2 and PIM6, and synthetic PIM1 and
PIM2 analogues inhibit LPS/TLR4-induced cytokine response
independently of TLR2, SIGN-R1 and mannose receptor [18,19].
Suppression of ovalbumin-induced allergic airway eosinophilia, a
model dependent on LPS response [32], by natural or synthetic
PIMs, and by a PIM2 analogue was reported [33–35]. Thus, not
only complex mycobacterial lipoglycans like ManLAM and LM,
but also small molecular weight PIMs are potent inhibitors of host
inflammatory responses.
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membranes [36] and to modify the signalling machineries of rafts/
microdomains [37]. LAM GPI anchor PIM6 competitively
inhibited LAM insertion into plasma membranes, likely into
specialized domains enriched in endogenous GPI-anchored
molecules [36]. Although TLR4 is a major receptor for the
cellular response to LPS, cells need to express co-receptors such as
the GPI-anchored CD14 or MD2 to mount a full response to LPS.
MD2 is indeed necessary for the processing and membrane
expression of TLR4 as well as for LPS signalling [38–40] while
CD14 is required for the LPS binding to MD2/TLR4 and
subsequent signalling [41,42].
Here, using synthetic PIM1 and PIM2 analogues, we analyzed
the mode of action of PIM anti-inflammatory effects. We
investigated LPS binding on TLR4/MD2/CD14 expressing cells
and found that PIMs inhibit this step and more specifically the
LPS binding to CD14. By using a shorter form of LPS, rough-LPS,
that stimulates TLR4 pathway independently of CD14 [41], we
then discriminated between CD14-dependent and CD14-inde-
pendent anti-inflammatory effects of PIMs on the LPS-induced
response. Our data show that PIM1 and PIM2 analogues inhibit
the LPS-induced TNF production by a CD14-dependent pathway
while the IL-12 p40 inhibition is CD14-independent, suggesting
that PIMs have multifold inhibitory effects on TLR4 signalling
pathway.
Materials and Methods
Ethics statement
The study of immune responses to mycobacteria infections was
approved by the Regional ethics committee for animal experi-
ments (CL2008-011).
Mice
Six to 12 week old mice deficient for TLR2 [43], TLR4 [44],
CD14 (obtained from Freeman, M.W [45]), MD2 [39] and wild-
type C57Bl/6 mice were bred at the Transgenose Institute animal
facility (UPS44 TAAM, Orleans, France).
Synthetic PIMs
PIM1 containing a C16 and a C18 chain in the glycerolipid unit
(2-O-a-D-mannopyranosyl-1-O-phosphatidyl-D-myo-inositol), to-
gether with the PIM1 isomer (1-O-a-D-mannopyranosyl-2-O-
phosphatidyl-D-myo-inositol), PIM2 mimetic [1,3-bis-(a-D-manno
pyranosyl)-2-O-phosphatidyl glycerol], and the reference com-
pound phosphatidyl inositol (PI, 1-O-phosphatidyl-D-myo-inositol),
were prepared as described [19].
LPS binding to cells
Human embryonic kidney (HEK) 293 cells were obtained from
the Centre for Applied Microbiology and Research (Porton Down,
Salisbury, Wiltshire, UK) and were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum, 100 U/mL penicillin, 100 mg/mL streptomycin and
2 mm L-glutamine and maintained at 37uC in a humidified
atmosphere of 5% CO2. HEK293 cells transfected with TLR4/
MD2/CD14 (HEK-MTC) were obtained from InvivoGen (San
Diego, CA) and maintained in the same medium as above
supplemented with Hygrogold (InvivoGen) and blastocidin
(InvivoGen). HEK-MTC cells (1610
6 cells in 50 ml in DMEM
10% FCS) were incubated with 10 mg/mL of PIM or vehicle for
30 min at 37uC under gentle agitation prior incubation with
biotinylated smooth LPS (S-LPS; Escherichia coli, serotype
O111:B4, InvivoGen) at a final concentration of 2.5 mg/mL
prepared in DMEM 10% FCS for 15–20 min. Cells were washed
with ice cold PBS and stained with streptavidin-FITC on ice. After
fixation with 3% paraformaldehyde, binding of S-LPS-biotin to
cells was measured on a BD FACS Calibur
TM. S-LPS-binding on
bone marrow derived macrophages (see below) was also
investigated by using DMEM supplemented with 0.1% FCS and
a final concentration of 5 mg/mL of S-LPS-biotin prepared in
DMEM 0.1% FCS and S-LPS-binding was measured with a BD
FACS Canto
TM II.
LPS binding to soluble CD14
Soluble recombinant mouse CD14 was coated overnight at 4uC
(5 mg/mL on Nunc 96-well plates; R&D systems, Abingdon, UK)
and non specific binding saturated with 2% BSA in PBS for 1 hr at
37uC. The plates were washed three times in PBS before
incubation with synthetic PIMs (10 mg/mL; 1 hr at 37uC) before
addition of biotinylated S-LPS for 2 hrs at 37uC (100 ng/mL,
InvivoGen) in PBS containing 1% of fetal calf serum. Alterna-
tively, 0.1% serum from wild-type or LBP-deficient mice [46] was
used, as indicated. Unbound S-LPS-biotin was removed with four
PBS washes, and bound S-LPS-biotin was detected with
horseradish peroxidase avidin D conjugate (1/2000, Vector
laboratories) diluted in 1% BSA in PBS. After addition of the
ABTS substrate (2,29-azino-bis-(3-ethylbenzthiazoline-6-sulfonic
acid at 0.3 g/L in 0.1 M anhydrous citric acid containing 0.3%
H2O2), absorbance at 405 nm was measured with a microplate
reader (Bio-Tek Instrument, INC). Competition with increasing
concentrations of ultrapure S-LPS (E. coli, serotype O111:B4,
InvivoGen, San Diego, CA) was performed to assess binding
specificity.
Cell culture
Murine bone marrow cells were isolated from femurs and
cultivated (10
6/mL) for 7 days in DMEM supplemented with
2 mM L-glutamine, 20% horse serum and 30% L929 cell-
conditioned medium as source of M-CSF. After further three days
in fresh medium, the cell preparation contained a homogenous
population of macrophages (97–98% CD11b
+F4/80
+). The bone
marrow derived macrophages (BMDM; 10
5 cells/well) in DMEM
supplemented with 2 mM L-glutamine and 0.1% FCS were
stimulated with 100 ng/mL of S-LPS (E. coli, serotype O111:B4,
CD14-dependent, ultrapure S-LPS from InvivoGen or Sigma, St
Louis, MO), 0.5 mg/mL of synthetic bacterial lipopeptide
Pam3CSK4 ([S-[2,3-bis-(palmitoyloxy)-(2-RS)-propyl]-N-palmi-
toyl-(R)-Cys-(S)-Ser-Lys4-OH], tri hydro-chloride, EMC Micro-
collections, Tuebingen, Germany), 30 ng/mL Malp2 (S-(2,3-bis
Acyloxypropyl)-cysteine-GNNDESNISFKEK, Alexis Biochemi-
cals, Lausanne, Switzerland), 0.125 mM of CpG ODN1826
(tccatgacgttcctgacgtt, Invivogen), 3 mM Taxol (Alexis). A CD14-
independent, rough-LPS (Re-LPS; E. coli, serotype 515, Alexis)
was also used, as indicated. Lyophilised PIM preparations were
solubilised in DMSO and added to the cultures at the indicated
concentration 30 min prior to the stimuli in a solution containing
a maximum non-cytotoxic, 1% DMSO final concentration.
Vehicle controls at the relevant DMSO concentration are
included in each experiment. PIMs were incubated in presence
or absence of 5 mg/mL recombinant mouse CD14 Fc chimera
(endotoxin ,1.0EU/mg protein; R&D system). The macrophages
were activated with IFN-c (500 U/mL) to study IL-12 release, and
the supernatants harvested after 24 hours for further analysis.
Absence of cytotoxicity of the stimuli was controlled using MTT
incorporation. To control PIMs anti-inflammatory activity on
human embryonic kidney (HEK) cells, HEK-MTC cells (6610
4
cells/well) were stimulated with S-LPS in the presence of PIM
CD14 Involvement in PIM Inhibition of Inflammation
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e24631analogues as above and human IL-8 concentration was measured
in the supernatant after overnight incubation.
Cytokine ELISA
Supernatants were harvested and assayed for cytokine content
using commercially available ELISA reagents for murine TNF,
murine IL-12 p40, and human IL-8 (Duoset R&D Systems).
Statistical analysis
Statistical significance was determined with Graph Pad Prism
software (version 4.0, San Diego, CA) by one or two way
parametric ANOVA test followed by Bonferroni post-test. P
values,0.05 were considered statistically significant.
Results
Interference of PIMs with LPS binding to cells
We showed previously that synthetic PIM1 and PIM2 mimetic
(Figure S1) inhibit TNF and IL-12 p40 release by macrophages
stimulated with low dose LPS ([19] and Figure 1A, B) at
micromolar concentrations (Figure 1C, D). We thus asked whether
PIMs could interfere with LPS-binding to cells (Figure 1E–J). By
using HEK cells transfected with TLR4, MD2 and CD14, we
showed that binding of biotinylated smooth LPS (S-LPS; E. Coli
serotype O111:B4) was partially inhibited by PIM1 (Figure 1F), a
PIM1 isomer (isoPIM1) (Figure 1G) and a PIM2 mimetic (Figure 1I)
but not by phosphatidyl inositol (PI; Figure 1E) or by a deacylated
PIM2 mimetic (deAcPIM2) control (Figure 1H). Excess of
unlabelled S-LPS competed only partially the binding of
biotinylated S-LPS (data not shown), although to the same extent
as PIMs, indicating a non-saturable, and maybe partially non-
specific cellular binding of biotinylated S-LPS. However, no
binding of S-LPS-biotin was detected on HEK cells in the absence
of TLR4/MD2/CD14 (Figure 1J). The inhibition of S-LPS
binding (Figure 1K) was accompanied with an inhibition of IL-8
release by S-LPS-stimulated HEK cells (Figure 1L). PIM1,
isoPIM1 and PIM2 mimetic also affected S-LPS-binding to
primary macrophages (Figure S2). Thus, there was a partial
decrease of S-LPS-biotin binding to TLR4/MD2/CD14 express-
ing HEK cells as well as primary macrophages in the presence of
PIMs.
Synthetic PIM analogues potently inhibit TLR4 and TLR2
induced pathways
We showed previously that the inhibitory effects of the natural
PIM6 fractions were preferentially targeted to the TLR4 signalling
pathway, although the specificity was not absolute for IL-12 p40
release [19]. Using more potent synthetic PIM1 and PIM2
analogues, we readdressed TLR specificity. Specific TLR4 agonist
S-LPS, TLR2/TLR1 agonist Pam3CSK4, TLR2/TLR6 agonist
Malp2, and TLR9 agonist CpG, were used to activate
macrophages in the absence or in presence of PIM derivatives.
Synthetic isoPIM1 and PIM2 mimetic inhibited the production of
TNF or IL-12 p40 (not shown) after stimulation by Malp2 or
Pam3CSK4 (Figure 2A, B), slightly less potently than they inhibited
S-LPS response (Figure 2C), while they did not inhibit TNF
release after stimulation by CpG (Figure 2D). Further, the
inhibition of Malp2 or Pam3CSK4 induced TNF could be seen
even in the absence of TLR4 (Figure 2E, F) indicating that this
effect is independent of the TLR4 pathway. Conversely, the
inhibition of S-LPS response could be seen in the absence of TLR2
(Figure 2G). Therefore, the inhibitory effects of synthetic PIM1
and PIM2 analogues target both TLR2 and TLR4 pathways.
Not only ampiphilic, acylated TLR agonists, but also Taxol
is inhibited by PIM
The TLR2 and TLR4 ligands tested above were acylated,
amphiphilic molecules. Since LAM were shown to form micelles
[47] and PIMsmay also do so,we next wantedto excludethat PIMs
act by scavenging the different acylated TLR4-agonist S-LPS, or
TLR2-agonists Pam3CSK4 and Malp2. We thus asked whether
PIMs could also inhibit macrophage activation triggered by Taxol,
a TLR4 agonist of a different molecular class [48,49]. The
contribution of potentially contaminating endotoxins in this
stimulation was excluded by pre-incubating Taxol with polymyxin
B at a concentrationsufficientto neutralise100 ng/mLofLPS(data
not shown).As shown inFigure 3A,Taxol is not acylated, it requires
the presence of TLR4 to stimulate TNF release by bone marrow-
derived macrophages (Figure 3B), and Taxol stimulation is potently
inhibited by isoPIM1 and PIM2 mimetic but not by PI and
deAcPIM2 mimetic controls (Figure 3C). Thus, a TLR4 ligand
unlikely to form micelles is also susceptible to PIM inhibition.
Interference of PIM analogues with smooth LPS binding
to CD14
Since synthetic PIM analogues could target both TLR2 and
TLR4 pathways we hypothesized that they may interact with a co-
receptor common to TLR2 and TLR4. CD14 was a likely
candidate. Indeed, natural PIM2 from M. Kansasii was shown to
interact with CD14 [50] and S-LPS binding was shown to depend
on the presence of CD14 [51]. We first confirmed that S-LPS
binding depended on the presence of CD14 as S-LPS binding was
essentially absent in CD14-deficient BMDM macrophages, while
it was only slightly reduced in TLR4-deficient macrophages and
similar in MD2-deficient and wild-type macrophages (Figure S3).
We then testeddirectly theabilityofPIMstointerferewithS-LPS
binding to soluble CD14 (sCD14) in presence of serum. Indeed,
LPS-binding protein (LBP) present in serum increases LPS binding
to sCD14 (not shown; [52]). S-LPS-biotin binding to sCD14 coated
on a solid phase was strongly inhibited by PIM1, isoPIM1 and PIM2
mimetic but not by PI and deAcPIM2 mimetic controls (Figure 4).
To avoid the contribution of LBP in this interaction, we compared
S-LPS-binding to sCD14 in fetal calf serum (Figure 4A), or in serum
from wild-type (Figure 4B) or LBP-deficient mice (Figure 4C).
Inhibition of S-LPS-biotin binding to sCD14 by PIM1, isoPIM1 and
PIM2 mimetic but not by PI and deAcPIM2 mimetic controls
occurred in mouse serum from wild-type or LBP-deficient mice,
thus in the presence or in the absence of LBP. The inhibition of S-
LPS binding to sCD14 by PIM1 was slightly weaker than the
inhibition by isoPIM1 or PIM2 mimetic, similar to the effect seen on
whole cell S-LPS-binding. Binding of biotinylated S-LPS was
effectively competed by unlabelled S-LPS in this system (Figure 4D).
To address the functional relevance of this interaction, we asked
whether soluble CD14 might ‘‘scavenge’’ some PIM molecules
and reduce PIM inhibition on S-LPS-induced TNF response.
Addition of sCD14 had essentially no effect on isoPIM1 or PIM2
mimetic inhibition of S-LPS-induced TNF (Figure S4A). Soluble
CD14 was used at a concentration effective for restoring some S-
LPS functional effect in CD14-deficient macrophages (Figure
S4B). Therefore, anti-inflammatory PIMs can prevent S-LPS
binding to sCD14, in an LBP-independent way, but CD14 may
not be directly involved in PIM inhibitory effects.
PIM inhibition of TLR2-induced cytokine responses is
independent of CD14
CD14 is able to recognize different ligands beside LPS and it
has been involved in TLR2-signaling induction in response to
CD14 Involvement in PIM Inhibition of Inflammation
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whether CD14 was an obligatory co-receptor for the anti-
inflammatory effects of PIMs on the TLR2 pathways. By using
macrophages from wild-type or CD14 KO mice, we show that
TNF stimulation by TLR2/TLR6 agonist Malp2 and TLR2/
TLR1 agonist Pam3CSK4 is retained in the absence of CD14
(Figure 5A–D). PIM analogues isoPIM1 and PIM2 mimetic, but
neither PI nor deAcPIM2 mimetic controls, inhibit these TLR2-
induced TNF responses both in wild type (Figure 5A, C) and in
CD14-deficient macrophages (Figure 5B, D). Similar results were
obtained for inhibition of IL-12 p40 release (data not shown).
Therefore, the inhibitory effects of synthetic PIM1 and PIM2
analogues on the TLR2 pathways are independent of CD14.
CD14 requirement is associated with PIM inhibition of
TNF, while CD14 is dispensable for PIM inhibition of IL-12
p40 release, after LPS/TLR4 activation
Concerning TLR4 pathway, CD14 has been shown to be
essential for the cellular binding and activity of smooth, S-LPS,
while rough LPS (Re-LPS) may bind and activate cells
independently of the presence of CD14 [41,42]. Using macro-
phages derived from CD14-deficient mice, we confirmed that S-
LPS induced a CD14-dependent release of TNF and IL-12 p40 at
low concentrations while concentrations of S-LPS above 1 mg/mL
induced TNF and IL-12 p40 release in the absence of CD14
(Figure 6A, B; [54,55]). Consistent with previous reports, Re-LPS
uses a CD14-independent pathway to induce TNF and IL-12 p40
(Figure 6C, D).
We then analyzed the role of CD14 in PIM inhibition of TLR4
pathway by comparing S- and Re-LPS responses. While S-LPS-
induced TNF production was strongly inhibited by isoPIM1 and
PIM2 mimetic (Figure 7A), CD14-independent TNF production
induced after Re-LPS stimulation was not inhibited by isoPIM1
and PIM2 mimetic, neither in wild type (Figure 7B) nor in CD14-
deficient macrophages (Figure 7C). In contrast, IL-12 p40
production induced either in a CD14-dependent manner by S-
LPS (Figure 7D), or in a CD14-independent manner with Re-LPS
(Figure 7E), was potently inhibited by isoPIM1 and PIM2 mimetic.
PIM anti-inflammatory effect on IL-12 p40 was not dependent on
the presence of CD14, since CD14 independent activation by
TLR4 agonist Re-LPS was also reduced by isoPIM1 and PIM2
mimetic in CD14 deficient macrophages (Figure 7F). Interestingly,
both CD14-dependent S-LPS induced TNF and IL-12 p40 were
inhibited by active PIMs, while CD14-independent Re-LPS-
induced IL-12 p40, but not TNF release, was inhibited by isoPIM1
and PIM2 mimetic. This was not merely a titration effect, since
even at lower doses of 3 to 10 ng/mL of Re-LPS were isoPIM1
and PIM2 mimetic inhibiting IL-12 p40 release while TNF
response was spared (Figure S5). The data indicated multifold
effects of PIMs on these pathways.
To further address the role of CD14 in the PIM inhibition of S-
LPS-induced response, we next investigated PIM anti-inflamma-
tory effect on the CD14-independent stimulation by high S-LPS
concentrations. Interestingly, TNF release stimulated by 1–3 ug/
mL of S-LPS, in a CD14-independent way (see Figure 6), was not
inhibited by PIM2 mimetic (Figure 8A), while CD14 independent
release of IL-12 p40 induced by S-LPS at 1–3 ug/mL concentra-
tions was strongly inhibited by PIM2 mimetic (Figure 8B). When
titrated in parallel by increasing the ratio of S-LPS over PIM
concentrations, TNF release was clearly less inhibited than IL-12
p40 release.
Thus, the fact that both CD14-independent Re-LPS-induced
IL-12 p40 release and CD14-independent, high dose S-LPS-
induced IL-12 p40 were inhibited by isoPIM1 or PIM2 mimetic
indicated that PIMs affect IL-12 p40 release independently of
CD14. Conversely, the fact that both CD14-independent Re-LPS-
induced TNF release and CD14-independent, high dose S-LPS-
induced TNF were not inhibited by isoPIM1 and PIM2 mimetic,
while CD14-dependent S-LPS induced TNF was inhibited,
suggested that PIM inhibition of TNF release targeted a CD14-
dependent pathway.
Discussion
Bacterial pathogens have developed numerous strategies to
undermine host innate responses and promote infection [56,57].
PRRs such as TLR2 or TLR4 are crucial to detect different
PAMPs and to coordinate signals that allow host cells to induce a
range of defence mechanisms, including oxidative stress, autoph-
agy and cell death. However, PRRs are also targets for
microorganisms to subvert both immune recognition and
intracellular signalling. Here we show that PIM1 and PIM2
analogues interfere with the pathways activated by both TLR2
and TLR4. M. tuberculosis and M. bovis were also shown to trigger
TLR2 and TLR4 pathways and produce TLR2 but also TLR4
agonists such as M. bovis tetra-acylated LM or M. tuberculosis LM
[19]. Mycobacteria thus produce on the one hand PAMPs that are
recognized by the host, and on the other hand molecules that can
interfere with the host innate immune responses, with a possible
balance between those. Indeed, PIMs inhibit macrophage
activation by M. tuberculosis LM [19].
We reported previously that some natural and synthetic PIMs
inhibit the expression of NO, a potent mycobactericidal mediator,
and of pro-inflammatory cytokines essential for host response to
mycobacteria such as TNF, IL-12p40 and IL-1 in vitro and in vivo
in response to LPS [19]. In line with this, natural or synthetic
PIMs [33,34] or a synthetic PIM2 analogue [35] suppress
ovalbumin-induced allergic airway eosinophilia, a model in which
LPS contaminant has been shown to play a crucial role [32]. Here,
in order to further understand the role that PIMs may play in
immune evasion, we thus addressed molecular mechanisms
Figure 1. Synthetic PIM analogues inhibit S-LPS-induced responses and binding to HEK cells expressing TLR4, MD2 and CD14. Bone
marrow derived macrophages (A, B) were stimulated with increasing concentrations of S-LPS in presence of 10 mg/mL of PIM2 mimetic or deAcPIM2
mimetic, or vehicle control, and TNF (A) and IL-12 p40 (B) were measured in supernatants after overnight incubation. Results are mean +/2 SEM from
n=6 mice from three independent experiments. PIM analogues were titrated (C, D) in the presence of 0.1 mg/mL S-LPS and a 10 mg/mL dose was
chosen as this concentration was sufficient for the active PIMs to strongly inhibit LPS-induced TNF (C) and IL-12 p40 (D) release without cytotoxicity.
(E–J) HEK cells stably transfected with TLR4, MD2 and CD14 were incubated with PI (E), PIM1 (F), isoPIM1 (G), deAcPIM2 mimetic (H) or PIM2 mimetic (I)
(10 mg/mL; dotted line) prior to incubation with biotinylated S-LPS (2,5 mg/mL) and streptavidin FITC (black line) or only streptavidin FITC (grey
histogram). Non transfected HEK cells were incubated with biotinylated S-LPS as a control (J). Results are from one experiment representative of three
independent experiments. (K) Percentage of S-LPS-binding to HEK-MTC cells in presence of vehicle, PI, isoPIM1, deAcPIM2 mimetic or PIM2 mimetic.
Results are the mean +/2 SD from three independent experiments. (L) Human IL-8 was measured in the supernatant after overnight S-LPS
stimulation of HEK-MTC cells. Results are mean +/2 SD from triplicates, from one experiment representative of three independent experiments.
*, p,0.05; **, p,0.01; ***, p,0.001 versus vehicle; h,p ,0.05; hhh,p ,0.001 indicate significant differences between PIM1 or isoPIM1 versus PI as
control; {{,p ,0.01; {{{,p ,0.001 indicate significant differences between PIM2 mimetic and deAcPIM2 mimetic as control.
doi:10.1371/journal.pone.0024631.g001
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inflammatory responses.
PIMs were described as mycobacterial adhesins mediating
binding to mammalian cells, but this effect was mostly attributed
to high order, polar PIM5 or PIM6 [58]. PIMs interact with several
cell surface receptors, including not only TLR2 but also CD1d
[59,60], and C-type lectins mannose receptor or DC-SIGN [31].
However, we showed previously that synthetic PIM1 or PIM2
mimetic analogues are not TLR2 agonists as they do not trigger
inflammatory responses at micromolar concentrations, and that
Figure 2. Synthetic PIM analogues inhibit TLR4 and TLR2 pathways but not TLR9. Macrophages from C57Bl/6 (A–D), TLR4 KO (E, F) or TLR2
KO mice (G) were activated with TLR2 agonist Malp2 (A, E) or Pam3CSK4 (Pam3; B, F), TLR4 agonist S-LPS (C, G) or TLR9 agonist CpG (D) in presence of
synthetic PI, isoPIM1, deAcPIM2 mimetic, PIM2 mimetic (all at 10 mg/mL), or vehicle. TNF production was measured in the supernatant after overnight
incubation. Results are from n=4–6 mice from two to three independent experiments (A–B, D–F) or n=2 mice from one experiment representative
of two independent experiments (C, G). ND: not detected. *, p,0.05; **, p,0.01 versus vehicle. hh,p ,0.01; hhh,p ,0.001 indicate significant
differences between isoPIM1 versus PI as control; {,p ,0.05; {{,p ,0.01 indicate significant differences between PIM2 mimetic and deAcPIM2 mimetic
as control.
doi:10.1371/journal.pone.0024631.g002
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24631CD1d, mannose receptor and SIGN-R1 are dispensable for PIM
inhibition of LPS-induced pro-inflammatory response in murine
macrophages [19]. We thus asked whether ‘anti-inflammatory’
PIM analogues could compete with LPS for binding on target
cells. Using flow cytometry to quantify LPS-binding to HEK cells
expressing LPS receptor and co-receptors TLR4, MD2 and CD14
or to primary macrophages, we show that anti-inflammatory
PIM1, isoPIM1 and PIM2 mimetic partially inhibited the binding
of biotinylated S-LPS to cells while inactive controls PI and non-
acylated, deAcPIM2 mimetic did not. The extent of competition
achieved with active PIM1 and PIM2 analogues was similar to that
observed with an excess of unlabelled S-LPS, although incomplete,
which might indicate some non-saturable and potentially non-
specific cellular binding of biotinylated S-LPS. Increased internal-
ization of TLR4 was unlikely responsible for the decreased S-LPS-
binding by PIMs. Indeed, PIMs prevented the down-regulation of
TLR4 mRNA expression seen 2 h after S-LPS-stimulation (data
not shown). Furthermore, macrophage pre-treatment with cyto-
chalasin D did not affect PIMs inhibitory activities (data not
shown).
Natural PIMs inhibited preferentially the TLR4 pathway [19],
suggesting a specific interaction of the PIMs with TLR4 or TLR4
pathway. However, using more active, synthetic PIM analogues
we demonstrated PIM inhibitory effects on macrophage responses
to either TLR2 or TLR4 agonists. The inhibition of TLR2/TLR1
agonist Pam3CSK4 and TLR2/TLR6 agonist Malp2 induced
responses occurred even in the absence of TLR4 and, conversely,
the inhibition of TLR4 agonist S-LPS response occurred in the
Figure 3. Synthetic PIM analogues inhibit TLR4-dependent,
Taxol induced TNF release. The antitumoral compound Taxol (A)
was used at increasing concentrations to stimulate macrophages from
C57Bl/6 and TLR4 KO mice, showing the TLR4 specificity (B). BMDM
from C57Bl/6 mice were stimulated with Taxol (3 mM) in the presence of
synthetic PI, isoPIM1, deAcPIM2 mimetic, PIM2 mimetic (all at 10 mg/mL),
or vehicle (C) and TNF concentrations were measured in the
supernatant after overnight incubation. Results are mean +/2 SD from
n=2 mice from one experiment representative of 2 to 3 independent
experiments. ND: not detected.
doi:10.1371/journal.pone.0024631.g003
Figure 4. Synthetic PIM analogues inhibit S-LPS-binding to
soluble CD14. The effects of PIMs on the binding of biotinylated S-LPS
to sCD14 was investigated in presence of 1% FCS (A, D), or 0.1% serum
from wild-type mice (B) or from LBP-deficient mice (C). Solid phase
adsorbed sCD14 was incubated (1 hr at 37uC) in the presence of
synthetic PI, PIM1, isoPIM1, deAcPIM2 mimetic and PIM2 mimetic (all at
10 mg/mL) or vehicle, before addition of biotinylated S-LPS (0.1 mg/mL;
2 hrs at 37uC). Binding specificity was determined by incubation with
increasing concentrations of non biotinylated S-LPS 1 hr prior to
biotinylated S-LPS (D). Results are expressed as percentage of
biotinylated S-LPS-binding to sCD14 as compared to incubation with
vehicle and are mean +/2 SD from three independent experiments.
***, p,0.001 versus vehicle; hhh,p ,0.001 indicate significant
differences between isoPIM1 versus PI as control; {{{,p ,0.001 indicate
significant differences between PIM2 mimetic and deAcPIM2 mimetic as
control.
doi:10.1371/journal.pone.0024631.g004
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24631Figure 5. Inhibition of TLR2 signaling by PIM analogues is independent of CD14. Macrophages from C57Bl/6 mice (A, C) or CD14 KO mice
(B, D) were incubated with synthetic PI, isoPIM1, deAcPIM2 mimetic, PIM2 mimetic (10 mg/mL) or control vehicle prior to stimulation with Malp2
(30 ng/mL; A, B) or Pam3CSK4 (Pam3; 0.5 mg/mL; C, D). TNF release was measured in supernatants after overnight incubation. Results are mean +/2
SD from n=4 mice from two independent experiments. *, p,0.05; **, p,0.01; ***, p,0.001 versus vehicle. hh,p ,0.01; hhh,p ,0.001 indicate
significant differences between isoPIM1 versus PI as control; {,p ,0.05; {{{,p ,0.001, indicate significant differences between PIM2 mimetic versus
deAcPIM2 mimetic as control.
doi:10.1371/journal.pone.0024631.g005
Figure 6. CD14-dependency of TNF and IL-12 p40 release induced by S-LPS versus Re-LPS. Macrophages from C57Bl/6 or CD14 KO mice
were stimulated with increasing concentrations of S-LPS (A, B) or Re-LPS (C, D). TNF (A, C) and IL-12 p40 (B, D) concentrations were measured in the
supernatants after overnight incubation. Results are mean +/2 SEM from n=4 mice from two independent experiments. *, p,0.05; **, p,0.01;
***, p,0.001 indicate significant differences between C57Bl/6 and CD14 KO.
doi:10.1371/journal.pone.0024631.g006
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PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e24631absence of TLR2. These results indicated that cytokine responses
to both TLR2 and 4 pathways can be inhibited by active PIMs
and suggested that PIMs were unlikely to act through an exclusive
interaction with TLR4. We hypothesised that PIMs may target a
co-receptor common to both TLR2 and TLR4. Since PIMs are
GPI-anchor, ampiphilic structures with acylated moieties, they
might interfere with the organization of supramolecular corecep-
tors/receptors multimeric complexes involved in both TLR2 and
TLR4 pathways. Indeed, LAM GPI anchor PIM6 competitively
inhibit the insertion of LAM into mononuclear cell plasma
membranes, likely into specialized domains enriched in endoge-
nous GPI-anchored molecules [36]. LAM were shown to modify
the signalling machineries of rafts/microdomains [37]. We
investigated CD14, one of the GPI-anchored proteins present in
hematopoietic cell microdomains, as a potential target candidate
for PIMs effect on the TLR2 and TLR4 pathways. Indeed, CD14
is necessary for S-LPS binding to cells and subsequent signalling
[51] and CD14 was also implicated as a first step in Pam3CSK4
recognition, inducing physical proximity with TLR2/TLR1 and
formation of the TLR2 signalling complex [61]. Natural PIM2
from M. kansasii was shown to interact with CD14 [50], and CD14
was implicated in mycobacterial LM and H37Ra LAM pro-
inflammatory activities [54,62]. Here, we documented the
inhibition of S-LPS binding to soluble CD14 by the anti-
inflammatory PIM1, isoPIM1 and PIM2 mimetic, but not by PI
or a deacylated PIM2 analogue. Thus, PIM derivatives interfered
with S-LPS binding to cells, and S-LPS-interaction with CD14 was
a likely target for this inhibition. However, PIM inhibition of S-
LPS-interaction with sCD14 was independent of the presence of
LBP. Further, PIM inhibition of S-LPS-induced TNF release was
not restored by addition of soluble CD14 to cells, indicating that
PIMs might not directly compete with S-LPS for binding to CD14,
but might rather affect an earlier step independent of LBP. Indeed,
several receptors found in serum are involved in LPS disaggre-
gation like HMGB1 [63], and might be considered.
We then addressed the functional implication of CD14 in PIM
anti-inflammatory effects by using macrophages deficient for
CD14. A partial CD14-dependency was reported for Malp2, but
not for Pam3CSK4, induced TNF response [42], while in our
hands Malp2-induced TNF release was CD14 independent. The
CD14 independent activation of TLR2 agonists Malp2 and
Pam3CSK4 was reduced by isoPIM1 and PIM2 mimetic,
indicating that active PIMs inhibit TLR2 signalling pathways by
a mechanism independent of CD14. We next asked whether PIM
interference with LPS-CD14 was a necessary component of the
functional inhibition of LPS-induced pro-inflammatory responses
by PIMs, at different levels. Active PIM analogues inhibited
CD14-independent Re-LPS-induced IL-12 p40 as well as CD14-
independent IL-12 p40 stimulation induced by high S-LPS
concentrations. However, while CD14-dependent TNF release
was potently inhibited by PIM1 and PIM2 analogues, neither
CD14-independent Re-LPS induced TNF release, nor CD14-
independent, high dose S-LPS-induced TNF were affected by
PIMs. Thus, CD14-independent IL-12 p40 release was inhibited
by PIM1 and PIM2 derivatives, while the CD14-independent TNF
release was not. These data suggest that PIMs affected IL-12 p40
release independently of CD14 while PIMs targeted a CD14-
dependent pathway for inhibition of TNF release.
We propose that PIMs may exert their inhibitory activity
through different ways, by inhibiting S-LPS binding to CD14, and
by interfering at another level. Indeed, CD14 participates in LPS-
induced TNF production in RAW cells and peritoneal macro-
phages while a CD14-independent pathway is used in Kupffer
cells [64]. Further, although CD14 is essential for cell binding and
activity of low dose smooth LPS, CD14 is dispensable at high
doses of S-LPS and for binding and cell activation by rough LPS
[41,42], confirming that TLR4 ligands can induce TNF and IL-12
production by different mechanisms which might not be equally
affected by PIMs. IL-12 p40 release after S-LPS stimulation
requires CD14 in macrophages, but other receptors such as
CD11b and CD18 (Mac-1) have been involved in the optimal
expression of IL-12 p40 and IL-12 p35 genes in response to LPS
or Taxol [65]. The regulation of IL-12 p40 expression is complex
[66]. One major regulator of IL-12 p40 production is the anti-
Figure 7. Differential inhibition of S-LPS versus Re-LPS induced TNF and IL-12 p40 release by PIMs. Concentrations of TNF (A–C) and IL-
12 p40 (D–F) in supernatants of wild type (A, B, D, E) or CD14-deficient (C, F) macrophages stimulated overnight with 100 ng/mL of S-LPS (A, D) or Re-
LPS (B, C, E, F) in the presence of synthetic PI, isoPIM1, deAcPIM2 mimetic, PIM2 mimetic (10 mg/mL), or vehicle. Results are mean +/2 SD from n=4
mice from two independent experiments representative of three independent experiments. ND: not detected. **, p,0.01; ***, p,0.001 versus
vehicle. hh,p ,0.01; hhh,p ,0.001 indicate significant differences between isoPIM1 versus PI as control; {{,p ,0.01; {{{,p ,0.001 indicate significant
differences between PIM2 mimetic versus deAcPIM2 mimetic as control.
doi:10.1371/journal.pone.0024631.g007
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inhibitory activity was not dependent on an increase in IL-10
expression as this cytokine is also inhibited by PIMs [19].
Combined activation of TLRs and other pattern recognition
receptors or co-receptors may result in agonistic or antagonistic
interactions and, in particular, the regulation of IL-12 expression
in response to TLR trigger is the net result of complex activation
and down-regulations implicating different kinases such as PI3K
or AKT (reviewed in [66,67]). The potential interference of PIMs
with other mechanisms or signalling pathways involved in the
expression of IL-12 will require further investigations.
In conclusion, as summarized schematically in Figure S6, we
show that PIMs inhibit macrophage activation in response to
TLR2 or TLR4 pathways at different levels. PIMs block LPS
binding to CD14, which may explain PIM inhibition of CD14-
dependent LPS functional responses through TLR4. However, not
all TLR responses need CD14, and this is particularly so for TLR4
response to rough LPS or to high dose smooth LPS, but also for
some TLR2 responses. In these cases, PIM inhibitory effect has to
be explained at another level, likely downstream of TLRs.
Supporting Information
Figure S1 Structure of synthetic PIM1, isoPIM1 and
PIM2 mimetics. Schematic representation of synthetic PIM1
showing the C16 and C18 acyl groups on glycerol chain positions
sn-2 and sn-1, an isomer of PIM1 (isoPIM1) carrying the
phosphatidyl group at position O-2 and the mannosyl residue at
O-1 of D-myo-inositol, the precursor PI, a synthetic mimetic of
PIM2 (PIM2 mimetic) bearing C16 and C18 acyl chains, and the
de-acylated precursor of the PIM2 mimetic (deAcPIM2 mimetic) as
control molecule.
(TIF)
Figure S2 Synthetic PIM analogues inhibit S-LPS-bind-
ing to macrophages. Bone marrow derived macrophages from
C 5 7 B l / 6m i c ew e r ei n c u b a t e dw i t h1 0 mg/mL (dotted line)
deAcPIM2 mimetic (A) or PIM2 mimetic (B) prior incubation
with 5 mg/mL of biotinylated S-LPS and streptavidine FITC
(black line). DeAcPIM2 mimetic did not displace S-LPS and was
superimposed with S-LPS plus vehicle (A). In controls,
macrophages were stained only with streptavidin FITC (grey
histogram). Results shown are from cells derived from one mouse
representative of cells from four different mice. (C) Percentage of
S-LPS binding to macrophages in presence of PIMs or vehicle.
Mean +/2 SD from n=4 mice from 2 independent experi-
ments. ***, p,0.001 versus vehicle. {{{,p ,0.001 indicate
significant differences between deAcPIM2 mimetic and PIM2
mimetic.
(TIF)
Figure S3 CD14 is an important co-receptor for S-LPS-
binding to macrophages. Bone marrow derived macrophages
from C57Bl/6 (A), TLR4 KO (B), MD2 KO (C) or CD14 KO
(D) mice were incubated with biotinylated S-LPS and streptavi-
dine FITC (black line). In controls, macrophages were only
incubated with streptavidine FITC (grey histogram). Results are
Figure 8. High S-LPS concentrations prevent TNF, but not IL-12 p40 inhibition by PIM2 analogue. Macrophages from C57Bl/6 mice were
stimulated with increasing doses of S-LPS in the presence of 10 mg/mL of deAcPIM2 mimetic and PIM2 mimetic or vehicle control. After overnight
incubation, TNF (A) and IL-12 p40 (B) concentrations were measured in supernatants. Results are mean +/2 SEM from n=6 mice from three
independent experiments. ***, p,0.001 versus vehicle. {,p ,0.05 indicate significant differences between PIM2 mimetic and deAcPIM2 mimetic.
doi:10.1371/journal.pone.0024631.g008
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PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24631from one mouse representative of four mice. (E) Percentage of S-
LPS-binding to macrophages compared to C57Bl/6 binding
level. Mean +/2 SD from n=4–8 mice from two to four
independent experiments. **, p,0.01, ***, p,0.001 versus
C57Bl/6.
(TIF)
Figure S4 Addition of sCD14 does not affect PIM
inhibition of S-LPS-induced TNF. (A) Macrophages from
C57Bl/6 mice were incubated with murine soluble CD14 (sCD14;
5 mg/mL) and PIMs (10 mg/mL) as indicated prior to stimulation
with S-LPS (100 ng/mL). (B) Wild type or CD14 KO macro-
phages were stimulated with S-LPS in the absence or in the
presence of murine soluble CD14 (sCD14; 5 mg/mL). TNF
concentration was measured in the supernatants after overnight
incubation. Mean +/2 SD from n=4 mice from two experiments
representative of three independent experiments. ***, p,0.001
versus vehicle. hhh,p ,0.001 indicate significant differences
between isoPIM1 versus PI as control, {{{,p ,0.001 indicate
significant differences between deAcPIM2 mimetic and PIM2
mimetic.
(TIF)
Figure S5 Differential inhibition of induced TNF and
IL-12 p40 release by PIMs at low doses of Re-LPS.
Concentrations of TNF (A) and IL-12 p40 (B) in supernatants of
CD14-deficient macrophages stimulated overnight with 3 or
10 ng/mL of Re-LPS in the presence of synthetic isoPIM1,
deAcPIM2 mimetic, PIM2 mimetic (10 mg/mL), or vehicle.
Results are mean +/2 SD from n=2 mice.
(TIF)
Figure S6 Schematic model of PIM interference with
TLR2 and TLR4 responses. PIMs block LPS binding to
CD14, which may explain the inhibition of PIM in CD14-
dependent LPS functional responses through TLR4. However, not
all TLR responses need CD14, as indicated for TLR4 response to
rough LPS or to high micromolar doses of smooth LPS, but also
for TLR2/TLR1 response to Pam3CSK4 and TLR2/TLR6
response to Malp2. In these cases, PIM inhibitory effect may be
downstream of TLRs. In addition, IL-12p40 expression requires
other surface molecules to be complete, such as CD11b and
CD18, and this may in part explain the different sensitivity of TNF
and IL-12p40 to the inhibition by PIMs.
(TIF)
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